You are here: Home
Categories

Precursor PSA (p2PSA):

1. Prostate Cancer Screening
Prostate cancer screening refers to testing for disease in healthy, asymptomatic populations, where diagnosis is the identification of disease among individuals with signs or symptoms. The goal of screening ...
2. Beyond the Abstract - The role of biopsy core number in selecting prostate cancer patients for active surveillance, by Guillaume Ploussard, MD and Alexandre de la Taille, MD
BERKELEY, CA (UroToday.com) - Active surveillance (AS) entails a strategy by which selected men are managed expectantly with the intention of applying potentially curative treatment in case of signs of ...
3. Beyond the Abstract - Anxiety and distress during active surveillance for early prostate cancer, by Roderick C.N. van den Bergh, MD, et al.
BERKELEY, CA (UroToday.com) - The present study found that the majority of men with early prostate cancer (PC) included in a protocol-based program for active surveillance (AS) show favorable anxiety and ...
4. Beyond the Abstract - Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study, by Roderick van den Bergh, MD, et al.
BERKELEY, CA (UroToday.com) - Screening for prostate cancer has the potential of decreasing the number of deaths due to this disease, but also knocks the lid off Pandora’s box.
5. Beyond the Abstract - A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer, by Monique J. Roobol, MD, et al.
BERKELEY, CA (UroToday.com) - Despite recent results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) that show relative mortality reduction up to 30% in favor of screening,
6. Beyond the Abstract - Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit, by Pim J. van Leeuwen, MD
BERKELEY, CA (UroToday.com) - The European Randomized Study of Screening for Prostate Cancer (ERSPC) has demonstrated that screening has the potential for reducing mortality from prostate cancer (PC). ...
7. Beyond the Abstract - 'Prostatic evasive anterior tumours': The role of magnetic resonance imaging, by Nathan Lawrentschuk, MD and Neil E. Fleshner, MD
BERKELEY, CA (UroToday.com) - In this recent article, we review our experience and delineate the role of magnetic resonance imaging (MRI) in identifying patients presenting with a raised prostate-specific ...
8. Beyond the Abstract - Expression and localization of hypoxia proteins in prostate cancer: Prognostic implications after radical prostatectomy, by Judith Jans, PhD
BERKELEY, CA (UroToday.com) - Biomarkers may facilitate predictions of disease progression and predictions of patients’ response to specific treatments.
9. Beyond the Abstract - The Epstein criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy, by Michael C. Lee, MD and Eric A. Klein, MD
BERKELEY, CA (UroToday.com) - Active surveillance is gaining popularity as a management strategy for newly diagnosed low-grade prostate cancer.
10. Beyond the Abstract - Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer, by Robert W. Veltri, PhD, and Sumit Isharwal, MD
BERKELEY, CA (UroToday.com) - We identified 75 men with available tissue from an initial diagnostic biopsy - of whom 71 had both benign-adjacent and cancer biopsy tissue as well as serum available from ...
11. Beyond the Abstract - Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies, by Fritz H. Schröder, MD
BERKELEY, CA (UroToday.com) - The European Randomized study of Screening for Prostate Cancer has shown that screening as executed in this trial reduces prostate cancer mortality by 20%[1] in the intention ...
12. Beyond the Abstract - Upgrading of Gleason score 6 prostate cancers on biopsy after prostatectomy in the low and intermediate tPSA range, by Daniela Colleselli, MD and Christian Schwentner, MD
BERKELEY, CA (UroToday.com) - Regarding prostate cancer (PCa), histological estimation of needle biopsy specimens from the prostate is the first step in diagnosis and treatment decision-making.
13. Beyond the Abstract - Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity, by Amit M. Algotar, MD, et al.
BERKELEY, CA (UroToday.com) - Aspirin is commonly used by men above age 50 for its protective effects towards cardiovascular disease. The risk of prostate cancer increases with age, especially after age ...
14. Beyond the Abstract - Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer, by D. Robert Siemens, MD
BERKELEY, CA (UroToday.com) - You can teach an old dog new tricks
15. Beyond the Abstract - Prospective comparison of PSA kinetics following two different prostate cancer brachytherapy planning methods: Preoperative and real-time intraoperative dosimetry planning, by Haim Matzkin, MD, et al.
BERKELEY, CA (UroToday.com) - Brachytherapy for localized prostate cancer is a mature treatment option.
16. Beyond the Abstract - Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI, by Hedvig Hricak, MD, PhD, et al.
BERKELEY, CA (UroToday.com) - A number of studies, including ours, have found the presence of T3 disease on MRI to be associated with adverse outcomes after radiation therapy or radical prostatectomy for ...
17. Beyond the Abstract - [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study, by Brian Le, MD and Willi
BERKELEY, CA (UroToday.com) - Prostate specific antigen (PSA), the primary means of diagnosing prostate cancer in the modern era, lacks specificity in differentiating benign from malignant disease.
18. Beyond the Abstract - Validation of the Partin Nomogram for prostate cancer in a national sample, by James B. Yu, MD
BERKELEY, CA (UroToday.com) - Our study investigates the performance of the Partin Nomogram using a cohort of patients identified in the National Cancer Institute, Surveillance Epidemiology, and End Results ...
19. Beyond the Abstract - Association of body mass index with prostate cancer biochemical failure, by Jay P. Ciezki, MD
BERKELEY, CA (UroToday.com) - Our study of prostate cancer patients’ outcomes relative to their body mass index (BMI) is interesting because of the lack of effect we observed between BMI and the study’s ...
20. Beyond the Abstract - It's time to depolarise the unhelpful PSA-testing debate and put into practice lessons from the two major international screening trials, by James W. Denham, MD, FRANZCR
BERKELEY, CA (UroToday.com) - It may interest non-Australian readers to know that there are huge regional variations in PSA testing prevalence and prostate cancer mortality across Australia.